TickerFacts.

Nuvation Bio Inc. (NUVB): Revenue

Annual figures by period end, from SEC filings.

$62.90M
Year ended 2025-12-31
$169.90M
Trailing 12 months to 2026-06-30
2023-12-31: $02024-12-31: $7.87M2025-12-31: $62.90M$62.90M
2023-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$62.90M+699.0%2026-03-02, From 2025-01-01
2024-12-31$7.87Mn/a2026-03-02, From 2024-01-01
2023-12-31$0n/a2025-03-06, From 2023-01-01

Revenue at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
Nuvation Bio Inc. (NUVB)2025-12-31$62.90M+699.0%
Fortress Biotech, Inc. (FBIO)2025-12-31$63.26M+9.7%
Tango Therapeutics, Inc. (TNGX)2025-12-31$62.38M+48.3%
Journey Medical Corp (DERM)2025-12-31$61.24M+11.1%
Enanta Pharmaceuticals Inc (ENTA)2025-09-30$65.32M-3.4%
Spero Therapeutics, Inc. (SPRO)2025-12-31$66.80M+39.2%
Kura Oncology, Inc. (KURA)2025-12-31$67.48M+25.2%
Aytu Biopharma, Inc (AYTU)2026-06-30$57.57M-13.3%
Rockwell Medical, Inc. (RMTI)2025-12-31$69.26M-31.8%

Compare NUVB, FBIO, TNGX, DERM side by side · Screen every company in Pharmaceutical Preparations ↗